Clinical Trial Update: Bevacizumab and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating bevacizumab in combination with interleukin-2 for metastatic or recurrent renal cell carcinoma; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Avastin (bevacizumab)
• Proleukin (aldesleukin)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2013-07-30